| Modern Eyes Llc | |
|
696 Washington St, Norwood, MA 02062-3546 | |
| (614) 284-3362 | |
| Not Available |
| Full Name | Modern Eyes Llc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 696 Washington St, Norwood, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518627058 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Graham Stetson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1184285801 PECOS PAC ID: 4789003567 Enrollment ID: I20200928002432 |
News Archive
Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.
Patients with high-risk, locally advanced rectal cancer could benefit from neoadjuvant chemotherapy before undergoing chemoradiotherapy, suggest the results of a pooled analysis.
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. We know that mutations in the genome of SARS-CoV-2 have occurred and spread, but what effect do those mutations have?
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Modern Eyes Llc 30 Lincoln St, Norwood, MA 02062-2120 Ph: () - | Modern Eyes Llc 696 Washington St, Norwood, MA 02062-3546 Ph: (614) 284-3362 |
News Archive
Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.
Patients with high-risk, locally advanced rectal cancer could benefit from neoadjuvant chemotherapy before undergoing chemoradiotherapy, suggest the results of a pooled analysis.
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. We know that mutations in the genome of SARS-CoV-2 have occurred and spread, but what effect do those mutations have?
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
› Verified 7 days ago
Dr. Steven Sharma, O.D Optometrist Medicare: Medicare Enrolled Practice Location: 31 Boston Providence Tpke, Lenscrafters Building, Norwood, MA 02062 Phone: 781-769-9290 | |
H. David Tabaie, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 95 Chapel St, First Floor, Norwood, MA 02062 Phone: 781-762-9018 Fax: 781-762-8878 | |
Graham Stetson, OD, MS Optometrist Medicare: Accepting Medicare Assignments Practice Location: 696 Washington St, Norwood, MA 02062 Phone: 781-352-4849 Fax: 781-634-8352 | |
Dr. Nabeel Khudairi, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 54 Cottage St E, Norwood, MA 02062 Phone: 781-762-5455 | |
Dr. Leigh C Kozak, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 95 Chapel St, Medical Eye Care Associates, Norwood, MA 02062 Phone: 781-333-2222 | |
Medical Eye Care Associates, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 95 Chapel St, Norwood, MA 02062 Phone: 781-762-9018 Fax: 781-762-0118 | |
Robert M. Condon, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 95 Chapel St, First Floor, Norwood, MA 02062 Phone: 781-762-9018 Fax: 781-762-8878 |